《新股消息》扞宇医疗科技传第三季来港上市 筹5亿美元
据《路透》旗下IFR引述消息指,上海扞宇医疗科技计划通过於第三季来港上市,筹集最多5亿美元。
扞宇医疗已向联交所提交上市申请,由中金及花旗担任联席保荐人。初步文件显示,该公司专注於结构性心脏病领域的创新医疗器械的研发及商业化。
扞宇医疗目前并未商业化任何管线产品,於2020年因提供宠物治疗及宠物医疗健康服务,录得收入约49万元人民币,全年录亏损1.28亿元人民币,对比2019年度录亏损4,813.3万元人民币。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.